The Library
Designer GLP1 poly-agonist peptides in the management of diabesity
Tools
Tools
Tools
Statham, L., Pelling, M., Hanson, Petra, Kyrou, Ioannis, Randeva, Harpal S. and Barber, Thomas M. (2023) Designer GLP1 poly-agonist peptides in the management of diabesity. Expert Review of Endocrinology and Metabolism, 18 (3). pp. 231-240. doi:10.1080/17446651.2023.2204976 ISSN 1744-6651.
|
PDF
WRAP-designer-GLP1-poly-agonist-peptides-management-diabesity-Barber-2023.pdf - Published Version - Requires a PDF viewer. Available under License Creative Commons Attribution Non-commercial No Derivatives 4.0. Download (444Kb) | Preview |
Official URL: https://doi.org/10.1080/17446651.2023.2204976
Abstract
Introduction:
To date, the 21st Century has witnessed key developments in the management of diabesity (a conflation of obesity and Type 2 Diabetes Mellitus [T2D]), including Glucagon Like Peptide 1 (GLP1) receptor agonist therapies, and recently the ‘designer’ GLP1 Poly-agonist Peptides (GLP1PPs).
Areas covered
A PubMed searc:h of published data on the GLP1PP class of therapies was conducted. The gut-brain axis forms complex multi-directional interlinks that include autonomic nervous signaling, components of the gut microbiota (including metabolic by-products and gram-negative cell wall components [e.g. endotoxinaemia]), and incretin hormones that are secreted from the gut in response to the ingestion of nutrients. The development of dual-incretin agonist therapies includes combinations of the GLP1 peptide with Glucose-dependent Insulinotropic Polypeptide (GIP), Glucagon (Gcg), Cholecystokinin (CCK), Peptide YY (PYY), and Glucagon-Like Peptide 2 (GLP2). Triple incretin agonist therapies are also under development.
Expert opinion:
At the dawn of a new era in the therapeutic management of diabesity, the designer GLP1PP class holds great promise, with each novel combination building on a preexisting palimpsest of clinical data and insights. Future innovations of the GLP1PP class will likely enable medically induced weight loss and glycemic control in diabesity to rival or even out-perform those resulting from bariatric surgery.
| Item Type: | Journal Article | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Subjects: | Q Science > QP Physiology R Medicine > RC Internal medicine |
||||||||
| Divisions: | Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School > Biomedical Sciences Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School > Biomedical Sciences > Translational & Experimental Medicine > Metabolic and Vascular Health (- until July 2016) Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School |
||||||||
| Library of Congress Subject Headings (LCSH): | Diabetes -- Treatment , Glucagon-like peptide 1 , Obesity -- Treatment | ||||||||
| Journal or Publication Title: | Expert Review of Endocrinology and Metabolism | ||||||||
| Publisher: | Taylor & Francis | ||||||||
| ISSN: | 1744-6651 | ||||||||
| Official Date: | 2023 | ||||||||
| Dates: |
|
||||||||
| Volume: | 18 | ||||||||
| Number: | 3 | ||||||||
| Page Range: | pp. 231-240 | ||||||||
| DOI: | 10.1080/17446651.2023.2204976 | ||||||||
| Status: | Peer Reviewed | ||||||||
| Publication Status: | Published | ||||||||
| Access rights to Published version: | Open Access (Creative Commons) | ||||||||
| Date of first compliant deposit: | 5 June 2023 | ||||||||
| Date of first compliant Open Access: | 5 June 2023 | ||||||||
| Related URLs: |
Request changes or add full text files to a record
Repository staff actions (login required)
 |
View Item |
Downloads
Downloads per month over past year
